Oddity Tech (ODD) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.61 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 9.52%. A quarter ago, it was expected that this online retailer of cosmetics and beauty products would post earnings of $0.13 per share when it actually produced earnings of $0.20, delivering a surprise of 53.85%. The ...

As the retail industry braces for profits to take a hit from tariffs, Oddity Tech is bucking the trend and raising its outlook after another quarter of outsized growth, the company said Tuesday. The beauty and tech retailer behind Il Makiage and Spoiled Child hiked both its earnings and profit guidance for fiscal 2025 and said it isn't weighing price increases to weather the impact of new levies. "We have other mitigating initiatives, and we'll have to see ultimately where tariffs shake out. There's also di ...

First quarter net revenue of $268 million, up 27% year-over-yearFirst quarter adjusted EBITDA of $52 millionFirst quarter net income of $38 million and first quarter adjusted net income of $42 millionFirst quarter operating cash flow of $88 million and free cash flow of $87 million NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the first quarter ended March 31, 2025. “Our Q125 results exceeded our expectations across all metrics and allo ...

Oddity ( ODD ) is not your average beauty retailer. It is a digital native beauty player that bypasses classical retailers and sells directly to consumers with outstanding profitability and efficiency. The key to the businessEx-hedge fund analyst with a strong interest in finding winners and losers in industries where corporate strategy matters most. I focus on analysing the market structure, competitive positioning and strategic catalysts that lead to money-making ideas in varying time horizons. Enjoy read ...

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. ("ODDITY") (NASDAQ:ODD), today announced that it will release its first quarter 2025 financial results after the market close on Tuesday, April 29, 2025, to be followed by a conference call on Wednesday, April 30, 2025, at 8:30 a.m. Eastern Time. Conference Call Details: To participate in the conference call, please dial 1-877-407-9208 (US) or 1-201-493-6784 (international). To access the call, please reference the company name and call title: OD ...

After reaching an important support level, Oddity Tech (ODD) could be a good stock pick from a technical perspective. ODD surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.One of the three major moving averages, the 50-day simple moving average is commonly used by traders and analysts to determine support or resistance levels for different types of securities. However, the 50-day is considered to be more important since it's the first marker of an up or down trend.ODD ...

Group 1 - Oddity Tech (ODD) has reached a significant support level and shows potential for investors from a technical perspective, having recently broken through the 20-day moving average, indicating a short-term bullish trend [1] - The 20-day simple moving average is a widely used trading tool that helps smooth out price fluctuations and provides more trend reversal signals than longer-term moving averages, with a price above this average indicating a positive trend [2] - ODD shares have increased by 12.4% over the past four weeks, and the company holds a Zacks Rank 3 (Hold), suggesting potential for continued gains [3] Group 2 - Positive earnings estimate revisions further strengthen the bullish outlook for ODD, with no earnings estimates lowered in the past two months and three raised estimates for the current fiscal year, leading to an increase in the consensus estimate [3] - The combination of favorable earnings estimate revisions and the stock hitting a key technical level suggests that investors should monitor ODD for potential gains in the near future [4]

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in Japan.The ODD in Japan adds to other important designations: the SAKIGAKE designation by Japan's MHLW in March 2023, the Orphan Drug ...

Oddity Tech (ODD -0.53%) reported its fourth-quarter and full-year 2024 earnings on February 26, 2025, highlighting strong growth and investments in future expansion. The company is seeing growth through repeat sales and its direct-to-consumer business, with new brands on the horizon in 2025 and 2026.Direct-to-Consumer Model Drives Superior PerformanceThe company's digital approach is delivering strong results amid broader industry headwinds. Oddity's direct connection with consumers enables precise invento ...

Financial Data and Key Metrics Changes - In 2024, the company achieved a revenue growth of 27% to $647 million and delivered adjusted EBITDA of $150 million at a margin of 23.3%, representing a 40% year-over-year increase in adjusted EBITDA [7][8] - The company generated $134 million of free cash flow, converting over 130% of net income into cash, and maintained strong momentum with revenue growth of 27% in Q4 [8][56] - The gross margin expanded to 72.7%, up 330 basis points year-over-year, exceeding guidance of 68% [53] Business Line Data and Key Metrics Changes - Both brands, Il Makiage and Spoiled Child, experienced double-digit revenue growth in 2024, with Il Makiage surpassing $500 million in revenue and Spoiled Child reaching $150 million [9][10] - The repeat sales metric increased significantly, with repeat revenue accounting for over 60% of total business revenue in 2024, up from less than 50% in previous years [12][82] Market Data and Key Metrics Changes - The company noted a shift towards online sales, which is expected to continue growing, with the belief that online penetration could double from current levels [14][77] - The company is strategically expanding its international presence, particularly in markets like the UK, Germany, and Australia, with positive early indications [25][26] Company Strategy and Development Direction - The company is focused on investing in growth areas such as Oddity Labs, new brands, and AI technologies to drive future growth [7][24] - The launch of brand three, a telehealth platform, is set for the second half of 2025, targeting medical-grade skin and body issues [28][100] - The company aims to leverage its direct-to-consumer model to maintain a competitive edge, avoiding excess inventory issues faced by wholesale brands [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to perform well despite macroeconomic challenges, citing strong repeat sales and a resilient business model [72][140] - The outlook for 2025 includes a commitment to achieving 20% revenue growth and a 20% adjusted EBITDA margin, despite planned investments in growth initiatives [59][60] Other Important Information - The company repurchased 3.6 million shares for approximately $147 million during 2024, with $103 million remaining on its buyback authorization [57][58] - The company exited 2024 with $169 million in cash equivalents and investments, maintaining a zero-debt position [58] Q&A Session Summary Question: Can you elaborate on your international strategy and why now? - Management indicated that the decision to accelerate international growth is strategic, focusing on smaller markets to spread growth effectively [71] Question: Are you seeing any weakness in consumer spending due to macro concerns? - Management noted that the shift to online sales is a significant factor, and they are not experiencing the same promotional pressures as competitors [75] Question: Can you provide insights on repeat purchases and growth from Il Makiage? - Management reported that repeat purchases account for over 60% of revenue, with a twelve-month net revenue repeat rate exceeding 100% [82] Question: What are the key milestones for brand three? - Management highlighted that brand three is set to launch with a focus on skin and body issues, with significant investments made to ensure a successful rollout [96][100] Question: How do you balance organic growth versus M&A for Oddity Labs? - Management stated that they are open to M&A opportunities to enhance capabilities, particularly in pharma, while also expanding their internal team [123]